CD274 and non-small cell lung carcinoma: Atezolizumab, with durvalumab and avelumab, is one of the three anti-PD-L1 monoclonal antibodies approved by the FDA and is employed in the treatment of urothelial carcinoma, non-small-cell lung cancer (NSCLC), small-cell lung cancer, triple-negative breast cancer, hepatocellular carcinoma, and melanoma [35].